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Abstract
AIM: To evaluate the outcome of transarterial chemoemb-
olization (TACE) in patients with unresectable hepatocellular
carcinoma (HCC) <5 cm in diameter eligible for radiofrequency
ablation (RFA).
METHODS: The treatment-related mortality, morbidity,
long-term survival, and prognostic factors of HCC patients
who had TACE and fulfilled the present inclusion criteria
for RFA were evaluated.
RESULTS: Of the 748 patients treated with TACE between
January 1990 and December 2002, 114 patients were also
eligible for RFA. The treatment-related mortality and morbidity
were 1% and 19%, respectively. Survival at 1, 3, and
5 years was 80%, 43%, and 23%, respectively. Older
age and a high albumin level were associated with a better
survival, whereas a high -fetoprotein level (AFP) and the
size of the largest tumor >3 cm in diameter were adverse
prognostic factors in multivariate analysis.
CONCLUSION: The morbidity, mortality, and survival data
after TACE for small HCCs eligible for RFA are comparable
to those reported after RFA in the literature. Our data
suggest the need for a randomized comparison of the
two treatment modalities for small HCCs.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most
common human cancers with poor prognosis if left
untreated, and only a small proportion is eligible for
intentional curative surgical resection[1,2]. Transarterial
chemoembolization (TACE) has been used as a palliative
treatment for patients with inoperable disease and those
with recurrence after resection. TACE is also used as a
(neo-)adjuvant treatment before or after surgical resection,
and before liver transplantation[3-6]. Hence, TACE is one of
the most frequently performed treatment modalities for HCC.
However, this treatment is still controversial and unsupported
by evidence of early randomized controlled trials[7-9]. Renewed
interest in this form of  treatment that has emerged as evidence
from recent randomized trials is in favor of this treatment[10,11].
A systematic review has convincingly shown a significant
survival benefit for treatment with chemoembolization
compared to no treatment[12]. Moreover, in some patients,
TACE has even shown a similar survival compared to certain
patients who underwent hepatic resection[13].
Local ablative, either open or percutaneous, techniques
are considered alternatives for hepatic resection, if HCC is
located either bilobar or multifocal rendering the disease
unresectable, or if  the patient has poor liver function reserve.
Radiofrequency ablation (RFA) for HCC is a relatively new
and popular local ablative technique. However, the lack of
sufficient long-term follow-up data to support the treatment
is well recognized. Strict criteria for RFA have not yet been
clearly defined, but in general RFA is considered suitable if
there are less than four lesions and the largest lesion is 5 cm
or less in diameter[4,14,15]. RFA may not be suitable for tumors
with portal vein, hepatic vein or vena cava involvement
and in patients with severe cirrhosis[16,17]. Given these criteria
and the reported promising results of  RFA, some patients
who might have been given TACE treatment prior to the
advent of  RFA may now be treated with RFA as the preferred
alternative. However, TACE is a better documented treatment
that is still used in many centers for HCC even if the tumor
is eligible for RFA. Currently there are no studies in the
literature directly comparing the results of the two treatment
modalities. Such comparative studies may not be available
in the near future because in most centers, RFA has been
employed for a short duration with no long-term follow-up
data, and not many centers have abundant experience in
both treatment modalities. The results of  TACE treatment
for unresectable HCCs <5 cm in diameter eligible for RFA
are also unknown because previous studies on TACE for
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HCC usually included a heterogeneous group of patients,
including those with large tumors and vascular invasion.
This study that applied the currently accepted RFA
inclusion criteria to our vast experience with TACE in patients
with HCC reports the outcome of these patients and the
factors associated with poor prognosis of  TACE treatment
in this particular group.
MATERIALS AND METHODS
A prospective database, which contained the data of all
patients with surgical and non-surgical treatments for HCC
at the Department of Surgery, Queen Mary Hospital, Hong
Kong, was used. All patients with newly diagnosed HCC
who had TACE as their initial treatment between January
1990 and December 2002 and had HCC with their largest
nodule being <5 cm in diameter were identified and
retrospectively analyzed. Other criteria included the number
of tumor nodules less than four, absence of severe cirrhosis
reflected by a Child’s C grading, and absence of portal vein
(intrahepatic or main trunk), hepatic vein or inferior vena
cava involvement.
Patients who had a diagnosis of  HCC, confirmed either
by biopsy or needle cytology, by two diagnostic imaging
modalities (contrast computed tomography (CT) scan,
magnetic resonance imaging or arteriography) showed typical
HCC nodules with arterial hypervascularization or one
diagnostic a persistently raised serum -fetoprotein level
(AFP) >400 ng/mL according to the Barcelona-2000 EASL
conference criteria[18]. We selected patients for TACE treatment
if they had inoperable bilobar disease or unilobar disease in
combination with sufficient hepatic function reflected by
a bilirubin level <50 mol/L and no metastatic disease.
Our technique of  TACE has been described elsew-
here[19,20]. Superselective cannulation of the artery supplying
the tumor was performed whenever possible. An emulsion
of cisplatin (1 mg/mL) and lipiodol (Lipiodol Ultrafluide;
Laboratoire Guerbet, Aulnay-Sous-Bois, France) at a volume
ratio of 1:1 was injected up to a maximum of 60 mL.
Embolization was performed with 1-mm2 particles of
gelatin-sponge (Spongostan, Johnson and Johnson Ltd,
Skipton, UK) mixed with 40 mg of gentamycin. Repetition
of  TACE treatment was tailored to response of  tumor and
tolerance of  liver rather than a fixed regimen. TACE was
repeated every 8-12 wk if there was tumor response (≥50%
decrease in tumor size according to World Health Organization
criteria) or if the tumor was static in size (<50% decrease
or <25% increase in tumor size). Treatment of  TACE was
terminated if  there was no evidence of  tumor on reassessment
CT (i.e. complete response), disease progression (≥25%
increase in tumor size or appearance of new lesions),
evidence of liver failure (rise of bilirubin >50 mol/L,
uncontrollable ascites or hepatic encephalopathy), severe
life-threatening complications such as liver abscess, or
extrahepatic metastasis.
Patient demographics, laboratory data, and tumor
characteristics were used for analysis. The Child-Pugh
classification (A or B) was used to categorize the patients
according to their status of liver cirrhosis and the new TNM
classification according to the American Joint Committee
on Cancer (AJCC)[21] was used for staging.
Continuous, normally distributed data were expressed
as mean±SD, and other continuous data were expressed as
medians with their interquartile range. Survival was analyzed
by Kaplan-Meier survival curves. Prognostic variables for
recurrence and survival were studied with univariate and
multivariate Cox proportional hazards regression. Variables
were categorized according to their quartile distribution
wherever possible. This regression yields a hazard ratio, which
may be interpreted as a relative risk within the average follow-
up period. We used sex, age, laboratory data (bilirubin,
albumin, AFP, platelet count) and tumor characteristics
(bilobar disease, size of largest tumor, number of tumors,
TNM stage) in a univariate Cox proportional hazard analysis.
Next, variables for which univariate test had a P value less
than 0.25 and biologically important variables (sex and age)
were included in a multivariate analysis with survival as the
outcome[22]. For model building, we applied backward
stepwise elimination of variables. All reported P values were
two-tailed. P<0.05 was considered statistically significant.
RESULTS
In the period between January 1990 and December 2002,
a total of 2 850 patients were seen at our outpatient clinic
for HCC and included in our database. Of these, 748 patients
with newly diagnosed HCC underwent TACE as their initial
treatment, and 200 patients had the largest tumor nodule
<5 cm in diameter. This group included 15 patients who
were considered unresectable during laparotomy and
subsequently given TACE as the primary treatment. Patients
who had more than three nodules (n = 60) subsequently
undergoing hepatic resection (n = 14), and those who had
portal vein (intrahepatic or main portal vein, n = 2) were
excluded from this study. There were no patients with hepatic
vein or inferior vena cava involvement. Of the remaining
124 patients, another 5 patients were excluded because of
Child’s C cirrhosis and an additional 5 patients did not fulfill
the criteria of HCC diagnosis used in this study. Hence,
this study involved 114 patients and all analyses were
performed in this group of  patients.
The diagnosis of  17 patients was confirmed by either
histology (n = 2) or cytology (n = 15). In 93 patients,
confirmation of  HCC was done by CT and hepatic
arteriogram, in 2 patients by magnetic resonance imaging
and hepatic arteriogram, and in the remaining 2 patients by
an ultrasound of the liver and a consistently increased AFP
combined with a hepatic arteriogram.
Patient characteristics are shown in Table 1. One patient
died as a direct result of  TACE treatment, the treatment-
related mortality was 1%. This patient had four previous
TACE sessions and developed both a liver abscess and
deterioration of  liver function after his 5th TACE treatment.
He subsequently developed sepsis and pneumonia and died
of respiratory failure. The overall treatment morbidity was
18%, the patient who died had two complications. Other
complications as a result of  TACE were hematoma at the
puncture site in the groin (n = 1, 1%) and liver failure, defined
as elevated bilirubin >50 mol/L, development of uncontrolled
ascites or hepatic encephalopathy (n = 20, 17%).
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Seventy-four patients died during our observation period
and the reasons for their death are given in Table 2. One
patient was lost to follow-up (1%). The 1-, 3-, and 5-year
survival rates were 80%, 43%, and 23% respectively (Figure 1).
The median survival was 31 months (95%CI: 24-38 mo).
Univariate and multivariate analyses are shown in
Tables 3 and 4, respectively. Higher age and a high albumin
level (above 41 g/L) were associated with a better survival
whereas AFP (above 81.50 ng/mL) and the size of the
largest tumor >3 cm in diameter were the risk factors for
death in the multivariate analysis.
DISCUSSION
We evaluated the morbidity, mortality and long-term
survival, and identified several independent risk factors for
death in patients who underwent TACE treatment with
patient and tumor characteristics that fulfilled all our present
criteria for RFA treatment. Although there are numerous
reports on the results of  TACE for inoperable HCC, many
included patients with large or advanced HCC with vascular
invasion for which the outcome is expectedly worse[3,5,6,19].
Such reports may give the impression that results after
TACE are worse than those after RFA, because most studies
of  RFA on HCCs focused on small HCCs and hence reported
more favorable results. To our knowledge, the survival and
prognostic factors in this specific group of patients with
HCC who were eligible for RFA but underwent TACE
treatment have not been reported before. As many patients
Table 1  Characteristics of 114 patients eligible for RFA but received TACE treatment
Characteristics Median          Interquartile range
Age (yr)      63    55-71
Gender: male/female (n)   87/27   76/24
Child’s grading (n, %)
    A      90        79
    B      24        21
HBsAg status (n, %)
Positive      82        71
Negative      32        28
TNM stage (n, %)
    Stage I      72        63
    Stage II      39        34
    Stage IIIA       1        1
    Stage IIIC       2        2
Number of tumor nodules (n, %)       1       1-2
    1      76        67
    2      32        28
    3       6        5
Size of largest tumor nodule (cm)     3.0   2.1-4.0
Tumor distribution (n, %)
    Unilobar      88        77
    Bilobar      26        23
Platelet count (×109/L)      98   72-128
Albumin (g/L)      37    33-41
Total bilirubin (mol/L)      17     12-24
Prothrombin time (s)    13.2 11.9-14.6
INR      1.1   1.0-1.2
AFP (ng/mL)      80    15-373
Number of TACE procedures       5       3-8
TACE: transarterial chemoembolization; HBsAg: hepatitis B surface antigen; INR: international normalized ratio; values are median with their interquartile range, unless
denoted otherwise.
Table 2  Causes of death in 74 patients after TACE treatment
Causes  n  %
Malignant cachexia 45 61
Bleeding   3   4
Hepatic failure   9 12
Respiratory failure   1   1
Multiorgan failure   2   3
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Survival of patients after TACE
who were considered to have unresectable HCC <5 cm in
diameter received TACE treatment before the RFA era,
this knowledge may be of specific interest to those who are
rethinking the concept of  TACE and RFA and wish to refine
their indications for both TACE and RFA treatments. With
the availability of  RFA, patients with small HCCs <5 cm in
diameter previously treated by TACE are now treated by
RFA instead as the preferred treatment in some centers,
although there is no direct evidence to show that RFA is
superior to TACE in terms of  treatment safety and long-
term survival benefit. The exact place of  local ablative
techniques and TACE in the overall management of  HCC
still needs to be determined. Offering a strict order of
treatment options to the patient, i.e. first hepatic resection,
then local ablative techniques and then TACE, may not be
fully justified. Indeed, percutaneous ethanol injection appears
to acquire similar results as resection for small HCC in
terms of  treatment efficacy, recurrence, and survival rates[23].
In addition, Bronowicki et al[24], found similar survival after
surgery and TACE, while the patients who underwent surgery
Table 3  Univariate analysis for prognostic factors of death
Variable           Hazard ratio   95%CI     P
Age (per yr) 1.01 0.99-1.03 0.347
Female sex 0.91 0.51-1.63 0.747
Bilirubin (mol/L)1
    5.00-11.75
    11.75-17.00 1.16 0.62-2.17 0.648
    17.00-24.00 1.67 0.88-3.18 0.116
    24.00-83.00 1.66 0.85-3.25 0.140
Albumin (g/L)1
    24-33
    33-37 0.72 0.38-1.37 0.310
    37-41 0.92 0.50-1.69 0.786
    41-50 0.40 0.20-0.81 0.011
AFP (ng/mL)1
    2-14.75
    14.75-81.50 1.42 0.71-2.86 0.320
    81.50-366 2.30 1.16-4.57 0.017
    366-11 470 1.99 1.03-3.83 0.041
Platelet count (×109/L)1
    36-72
    72-99 1.00 0.54-1.85 0.992
    99-128 1.26 0.66-2.39 0.486
    128-295 0.81 0.42-1.59 0.539
Bilobar disease 1.06 0.62-1.80 0.841
Largest tumor >3 cm 1.40 0.87-2.24 0.163
Child’s B grade2 1.67 0.97-2.88 0.065
AJCC TNM stage3
    Stage I
    Stage II 1.08 0.67-1.73 0.763
    Stage IIIA 0.00 0.00->100 0.971
    Stage IIIC 1.73 0.24-12.65 0.591
CI: confidence interval; AJCC: American Joint Committee on Cancer. 1Hazard ratio of bilirubin, albumin, AFP, and platelet count is given relative to the lowest quartile.
2Hazard ratio of Child’s B grade is given relative to Child’s A grade. 3Hazard ratio of AJCC TNM stage is given relative to stage I.
Table 4  Multivariate analysis for prognostic factors of death
Variable           Hazard ratio   95%CI  P
Age (per yr) 0.98 0.95-1.00                 0.044
Albumin (g/L)1
    24-33
    33-37 0.83 0.42-1.63                 0.586
    37-41 1.14 0.61-2.13                 0.685
    41-50 0.21 0.09-0.49               <0.0005
AFP (ng/mL)1
    2-14.75
    14.75-81.50 1.57 0.77-3.17                 0.209
    81.50-366 4.61 2.13-9.98               <0.0005
    366-11 470 3.72 1.77-7.85                 0.001
Largest tumor >3 cm2 1.64 1.00–2.69                 0.049
CI: confidence interval. 1Hazard ratio of albumin and AFP is given relative to the lowest quartile. 2Hazard ratio is given relative to the size of the largest tumor smaller
than 3 cm in diameter.
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were younger and had a better staging, and, just recently,
TACE has been shown to be as effective as hepatic resection
in certain patients[13]. Moreover, evidence from randomized
controlled trials comparing even two local ablative
techniques is hardly available, not to mention trials comparing
two different treatment modalities such as TACE and RFA.
Therefore, one must be careful not to jump to conclusions[25].
In patients who do not want surgery, which is still necessary
in a large proportion of  cases for RFA because of  tumor
location at the superior portion of the liver or close to the
adjacent viscera[26], TACE is still one of  the best options.
Furthermore, some centers may not have the availability
and/or equal expertise of all treatment options and may
stick to the use of  TACE as the preferred treatment for all
unresectable HCC.
Given the potentially curative intent of  RFA, many
clinicians consider RFA as the treatment of  choice for
unresectable small HCC, although long-term survival
results of  RFA are scarce[27]. In addition, complications and
treatment mortality after RFA are generally expected to be
fewer than those after TACE, and RFA may result in less
deterioration of liver function. The treatment mortality in
this study (1%), however, appears comparable to that of
RFA[28]. A recent literature review suggests that the treatment
morbidity of  RFA in the early reports is probably underes-
timated[28]. The treatment morbidity of  TACE for small
HCC in this study was 18%, which is comparable to the
complication rates of  13-20% after RFA for HCC reported
in some of the more recent studies[28,29]. The complication
rate is 14% in our preliminary experience with RFA in 86
patients with HCC between May 2001 and December 2002[30].
The 1-year survival rate of  the HCC patients treated by
TACE in the current study was 80%, which is comparable
to the 1-year survival observed after RFA for HCC in our
preliminary experience[30]. The 3-year survival rate of  43%
is also comparable with that of 33-50% in recent reports
of  more long-term survival results of  RFA for HCC[31,32].
In this study, the 5-year survival after TACE for HCCs
<5 cm in diameter that were eligible for RFA was 23%.
Data on 5-year survival rate after RFA for HCC are scarce.
In a recent study, Buscarini et al[33], reported a 5-year survival
rate of  33% after RFA for HCCs ≤3.5 cm in diameter,
which appears comparable to that after TACE for tumors
of a similar size in our study.
In this study, we did not directly compare our TACE
results to similar patients who underwent RFA treatment in
our institution. We have started RFA only 4 years before,
like many others, and long-term follow-up is unavailable
yet. Furthermore, most patients in this study were treated
with TACE in the era long before the availability of  RFA.
Naturally, a future comparison between similar patients
undergoing TACE and RFA within the same time-frame
will be made. Ultimately, however, a randomized controlled
trial may be needed. This study may serve as a reference to
compare present and future RFA series, as in many centers
that perform RFA, TACE is either losing ground or experience
with TACE is not so large in the first place. Our results of
TACE in patients with HCC <5 cm in diameter suggest
that the safety of  TACE and survival results may be
comparable to those of  RFA, which is an important message
for clinicians treating HCCs. This highlights the need for
randomized studies to compare the two treatment modalities
rather than simply considering RFA as the preferred
treatment based on perceived benefits.
RFA is still an evolving technique and it is therefore
understandable that there is a large diversity in indications
for RFA. Our inclusion criteria for RFA are consistent with
the reported criteria[14-17,27]. A largest tumor size ≤ 5 cm in
diameter, the number of tumors less than four and tumors
not invading or abutting major hepatic veins or portal vein
branches have all been reported as the inclusion criteria for
RFA. In our database of  HCC patients treated with TACE,
114 of  748 patients who underwent TACE treatment (15%)
fulfilled the criteria for RFA treatment. We found that a
high albumin concentration was associated with better
survival. We believe that this reflects the better liver function
of these patients compared to those with low albumin
concentrations. Indeed, it is reasonable to speculate that
patients with poor liver function may do better with local
ablative techniques, such as RFA, because these techniques
result in less liver damage than TACE. Child’s B grade liver
function did not appear to be an independent predictor in
the multivariate analysis because it possibly interacted with
albumin concentration. A higher age results in a risk reduction
of 2% per year. Others have found that age is an adverse
prognostic factor[34,35]. We cannot explain this interesting
observation but we propose that it might be related to
selection or, partially a more malignant behavior of HCC
in younger patients. In any case, age may not be a clinically
important factor that influences the clinician’s decision to
treat the patient with RFA or TACE. Both a high AFP,
which reflects tumor volume and perhaps also tumor
aggressiveness, and tumor size are associated with poorer
survival. These risk factors have been identified previously
in other prognostic studies of  TACE[35–38]. Patients with
tumors measuring between 3 and 5 cm performed worse
compared to those with smaller tumors when put on TACE
treatment. Perhaps this particular group may do better when
treated by local ablative techniques such as RFA. Advances
in RFA technology have allowed ablation of  larger HCC.
RFA may effectively treat tumors up to 5 cm in diameter
by using a clustered probe or by inflow occlusion with the
Pringle maneuver[4,30].
This is the first study that investigated the outcomes of
TACE for a group of  patients with HCC <5 cm in diameter
who would now be treated with RFA instead in many centers.
TACE for small HCC has been reported before but focused
mainly on the technical aspects, and those studies did not
specifically look at patients who were also eligible for RFA
treatment. Moreover, these are all Japanese studies with
mainly hepatitis C patients[39-41]. Our results compare favorably
with the results of  Nakao et al[39], (34% 3-year survival),
and are similar to the results of  Yamada et al[40], (47% 3-year
survival). Takayasu et al[41], have reported a 77% 3-year
survival in their patients with HCC <5 cm in diameter.
However, the mean tumor size was only 1.9 cm in their
study.
In conclusion, this study provides the morbidity, mortality
and long-term survival results of  a group of  patients who
were otherwise eligible for RFA treatment but received
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TACE. Our data, based on a retrospective analysis, suggest
that the immediate and at least the short-term and
intermediate-term survival results of  TACE for small HCC
may be comparable to those of  RFA reported in the
literature. The data may serve as a useful reference for
comparison to RFA treatment when long-term survival of
the latter treatment becomes available. This study highlights
the need for a prospective comparative study of the two
treatment modalities rather than simply replacing TACE
with RFA for small inoperable HCCs as the treatment of
choice, as what many centers are doing with the availability
of  this new technology. The identification of  the prognostic
factors may help in better selection of  patients for TACE
or RFA treatment.
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